SCHEMBL376435

SCHEMBL376435

NC(=NS(=O)(=O)c1ccc(Cl)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC=C(c3ccccc3)c3ccccc3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 3/20 0.42
LMNA P02545 3/20 0.42
BCL2 P10415 1/20 0.42
BCL2L1 Q07817 1/20 0.42
CTSK P43235 1/20 0.41
GAA P10253 2/20 0.39
F2 P00734 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38
VCAM1 P19320 3/20 0.38
CYP17A1 P05093 1/20 0.38
CYP21A2 P08686 1/20 0.38
CYP11B1 P15538 1/20 0.38
HTT P42858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13503908 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL376602 0.90 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL376603 0.90 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL13503543 0.90 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL376434 0.84 BCL2L1 (0.46) ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL3589313 0.83 BCL2L1 (0.58) BCL2BCL2L1
SCHEMBL13503607 0.83 BCL2L1 (0.58) BCL2BCL2L1
SCHEMBL376618 0.83 BCL2L1 (0.58) BCL2BCL2L1
SCHEMBL13503672 0.81 BCL2L1 (0.58) BCL2BCL2L1
SCHEMBL3601743 0.81 BCL2L1 (0.58) BCL2BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD ALDH1A1 2354/4885SMN1; SMN2 808/4885MEN1 4383/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD ALDH1A1 2354/4885SMN1; SMN2 808/4885MEN1 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.